Bio Green Med Solution, Inc. (BGMS) Annual Report: Major Developments, Strategic Transactions, and Key Risks for Investors

Company Overview

Bio Green Med Solution, Inc. (“BGMS”, formerly Cyclacel Pharmaceuticals, Inc.), headquartered at 200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey, is listed on the Nasdaq Capital Market under the trading symbol BGMS for its common stock and BGMSP for its preferred stock.

The company is registered as a “Non-accelerated filer” and a “Smaller reporting company” under SEC definitions, but it is not an emerging growth company. BGMS has confirmed ongoing compliance with SEC reporting obligations and electronic data submission requirements.

Key Price-Sensitive Developments

1. Major Equity Transactions and Reverse Stock Splits

• Conversion of Preferred Shares: BGMS disclosed that 1,000,000 shares of Series C Preferred Stock were converted into 11,042 shares of common stock, and 1,745,262 shares of Series D Preferred Stock were converted into 799,911 shares of common stock. This resulted in the investor holding 810,952 shares of common stock post-conversion.
• Reverse Stock Splits: On May 12, 2025, the company executed a one-for-sixteen reverse split of its common stock, followed by a one-for-fifteen reverse split on July 7, 2025. All share and per-share data in the financials have been retroactively adjusted to reflect these splits. These actions are typically undertaken to meet minimum bid price requirements for continued Nasdaq listing or to reduce share count, and can have significant impacts on share price and investor perception.

2. Strategic Acquisition: FITTERS Diversified Berhad

• On May 6, 2025 (amended July 7, 2025), BGMS entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL), a Malaysian investment holding company with interests in fire safety equipment, “Waste-To-Resource” services, and real estate development. Under this agreement, BGMS acquired all the ordinary shares of FITTERS’ Malaysia-based subsidiary, Fitters Sdn. Bhd.
• This transaction marks a significant international expansion and diversification into the fire safety materials and equipment market, as well as environmental services and real estate, potentially impacting BGMS’s future revenue streams, operational risks, and market valuation.

3. Disposal of Cyclacel Limited

• BGMS has disclosed the disposal of Cyclacel Limited, a noteworthy divestiture that could change the company’s business focus, operational risks, and financial results going forward.

Key Risks and Shareholder Considerations

• Continued Operating Losses and Going Concern: The company has a history of operating losses and expects to incur losses for the foreseeable future, raising substantial doubts about its ability to continue as a going concern.
• Liquidity Needs and Capital Raising: BGMS will need to raise additional capital to support its operations and strategic initiatives, which may lead to further dilution for existing shareholders and could restrict operations or force the relinquishment of certain rights.
• Nasdaq Listing Compliance: The reverse splits suggest efforts to maintain compliance with Nasdaq’s minimum bid price and listing requirements. Failure to comply could result in delisting, which would significantly impact liquidity and share value.
• Regulatory and Legal Risks: The company faces numerous regulatory risks, especially as it expands internationally, including exposure to stringent fire safety regulations in Malaysia, product liability, export controls, and changing tax laws.
• Competitive and Market Risks: BGMS operates in highly competitive and commoditized markets and faces risks from larger, better-resourced competitors, as well as macroeconomic uncertainties, foreign exchange volatility, and inflation.
• Cybersecurity and Data Risks: The company highlights exposure to security incidents, data loss, and other business disruptions.
• Dividends: BGMS may not pay dividends on its common stock in the foreseeable future, and its ability to pay preferred dividends is also a risk factor.

Share Capital and Outstanding Shares

As of March 24, 2026, BGMS had 5,519,456 shares of common stock outstanding. The company’s outstanding preferred stock (par value \$0.001) is also traded on Nasdaq (symbol: BGMSP).

Summary Table of Principal Risk Factors

• Dependence on key management and personnel
• No business interruption insurance – risk of unrecoverable losses
• Risks from raising additional capital and potential dilution
• Risks from trade policy changes, tariffs, and import/export regulation
• Highly competitive and commoditized industry
• Risks from delays or cancellations in projects and maintaining customer relationships
• Product liability, warranty claims, safety, and quality risks
• Regulatory risks in the U.S. and international markets
• Currency, interest rate, and inflation risks
• Risks related to compliance with U.S. securities law and Nasdaq listing
• Cybersecurity, data loss, and operational disruption risks
• Risks related to company’s ability to pay dividends on common and preferred stock
• Risks from reverse splits, future capital raises, and potential share price volatility

What Investors Should Watch

• The acquisition of FITTERS Diversified Berhad is a material transaction that could reshape BGMS’s business and risk profile, potentially boosting revenues but also exposing the company to new geographies and regulatory regimes.
• The execution of two consecutive reverse stock splits is a strong signal of efforts to maintain Nasdaq compliance and could affect share price volatility and investor sentiment.
• The company’s continued losses and need to raise capital, together with the possibility of further dilution, are critical for valuation and share price outlook.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should read the full SEC filings and consult their own advisors before making investment decisions. The author and publisher are not responsible for any losses or damages arising from reliance on this content.

View Bio Green Med Solution, Inc. Historical chart here